THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EASTERN-EUROPE EDITION)

Transcription

1 THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EASTERN-EUROPE EDITION) Feedback from 93 Eastern-European patient groups PUBLISHED JULY 2016

2 CONTENTS ABOUT THIS REPORT Page 1 WHAT DID PATIENT GROUPS IN EASTERN EUROPE SAY ABOUT PHARMA IN 2015? Summary of the industry-wide findings in Eastern Europe Page 3 SOME POINTS ABOUT THE EASTERN-EUROPEAN CORPORATE RANKINGS Page 6 WHAT CAN PHARMA COMPANIES DO TO IMPROVE THEIR CORPORATE REPUTATION? Page 7 A FEW COMMENTS FROM PATIENT GROUPS IN EASTERN EUROPE, 2015 Page 8 METHODOLOGY OF THE PATIENT-GROUP SURVEY Page 9 APPENDIX 1: Data on how patient groups in Eastern Europe see the pharmaceutical industry in 2015 Page 10 APPENDIX 2: Rankings of the 19 pharma companies for each of the 6 indicators of corporate reputation, as perceived by patient groups in Eastern Europe in 2015 Page 15 APPENDIX 3: Profiles of the 19 companies Page 24 APPENDIX 4: Profiles of the 93 respondent patient groups from Eastern Europe Page 45

3 LIST OF TABLES AND CHARTS BASED ON THE VIEWS OF PATIENT GROUPS IN EASTERN EUROPE Percentage of patient groups in Eastern Europe claiming familiarity with the company Page 2 Percentage of patient groups in Eastern Europe claiming familiarity, and which also worked with the company Page 2 Percentage of patient groups worldwide (by geographic region) stating that the pharma industry had an Excellent or Good corporate reputation in 2015 Page 3 % of patient groups (by geographic region) stating that pharma is Excellent or Good at BEING INNOVATIVE Page 5 % of patient groups (by geographic region) stating that pharma is Excellent or Good at PRODUCING HIGH- QUALITY PRODUCTS % of patient groups (by geographic region) stating that pharma is Excellent or Good at MANAGING ADVERSE NEWS ABOUT PRODUCTS % of patient groups (by geographic region) stating that pharma is Excellent or Good at HAVING FAIR PRICING POLICIES Page 5 Page 5 Page 5 Final ranking of pharma companies for corporate reputation in 2015, according to patient groups based in Eastern Europe, v. final ranking in Eastern Europe in 2014 Page 6 The percentage of patient groups from three Eastern-European countries that said pharma had an Excellent or Good corporate reputation in 2015 Page 6 If a pharma company wishes to improve its corporate reputation with patients and patient groups, which single strategy from the list below do you think would be MOST IMPORTANT for the company to follow? Please select only ONE option How do you think your organisation s members (or the people you represent) would rate the corporate reputation of the following healthcare sectors in 2015? Page 7 Page 11 What do you think has happened to the corporate reputation of the pharma industry over the past five years? Page 12 How good or bad do you think the pharma industry is in 2015 at carrying out the following activities (all of which influence their corporate standing with patients and patient groups in Eastern Europe)? Pages Companies with the most effective patient-centred strategy (rankings of 19 companies, 2015) Page 16 Companies providing the best high-quality patient information (rankings of 19 companies, 2015) Page 17 Companies with the best record on patient safety (rankings of 19 companies, 2015) Page 18 Companies with the most-useful high-quality products (rankings of 19 companies, 2015) Page 19 Companies with the best record of transparency (rankings of 19 companies, 2015) Page 20 Companies with the best record on integrity (rankings of 19 companies, 2015) Page 21 Rankings of the 19 pharmaceutical companies in Eastern Europe, 2015 v. 2014, ALPHABETIC ORDER Page 22 Rankings of the 19 pharmaceutical companies in Eastern Europe, 2015 v. 2014, HIGHEST TO LOWEST Page 23 Profile of 2015 s 93 respondent patient groups based in Eastern Europe by country Page 46 Geographic remit of 2015 s 93 respondent patient groups based in Eastern Europe Page 46 Profile of 2015 s 93 respondent patient groups based in Eastern Europe by therapy area Page 47

4 LIST OF TABLES AND CHARTS CONTINUED AbbVie page 26 Amgen page 27 AstraZeneca page 28 Bayer page 29 Boehringer Ingelheim page 30 Bristol-Myers Squibb page 31 Eli Lilly (Lilly) page 32 Gedeon Richter page 33 GSK page 34 Janssen page 35 Merck & Co page 36 Novartis page 37 Novo Nordisk page 38 Pfizer page 39 Roche page 40 Sandoz page 41 Sanofi page 42 Servier page 43 Teva page 44 profiles of the 19 companies, according to the patient groups in eastern europe that are familiar (or have worked) with them Each profile contains... company background information Annual revenue (latest-available year), comprising amount in currency, as quoted by the profiled company itself. = increase in revenue over the previous year or = decrease in revenue. The profiled company s main treatment subject areas (and areas of R&D). A mission statement from the profiled company. how the company has performed at the six indicators of corporate reputation The profiled company s performance at the six indicators of corporate reputation in 2015, according to the patient groups in Eastern Europe familiar with the company. The profiled company s performance at the six indicators of corporate reputation, according to the patient groups in Eastern Europe that have worked with the company. How the profiled company performed in Eastern Europe for different countries, compared with the company s averages in Eastern Europe in How the profiled company performed in Eastern Europe for different therapy areas, compared with the company s averages in Eastern Europe across all therapy areas in how the company ranks for corporate reputation compared with other companies The profiled company s rankings in Eastern Europe in 2015 for the six indicators of corporate reputation, compared with 18 other companies. The profiled company s rankings worldwide in 2015 for the six indicators of corporate reputation, compared with 47 other companies. profile of the patient groups familiar with the company Other companies that partner with a significant number of the profiled company s partner patient groups. The therapy areas and countries of the patient groups familiar with the profiled company. Janssen Pharmaceutical Companies of Johnson & Johnson

5 Costs have skyrocketed on older generic drugs. It is painful to know that we are paying American drug companies much more than people in other countries are paying for the same drugs. Local Romania-based patient group specialising in a neurological condition in 2016, patientview is publishing 20 corporate reputation of pharma reports, analysing the results from the 1,075 patient groups responding to the 2015 survey. specialty reports: cancer I circulatory conditions I diabetes I hiv/aids I hepatitis I neurological conditions I mental health I respiratory conditions I skin conditions I rare diseases (10 reports) geographic region reports (in addition to this current easterneuropean report): europe-wide I germany I global I italy I latin america I nordic I spain I uk I us (10 reports)

6 Contact details PatientView Registered office: One Fleet Place, London, EC4M 7WS, UK Tel: +44-(0) Registered in England, number: Data protection registration number: Z VAT registration number: GB Copyright 2016 PatientView Ltd. All rights reserved. This booklet is the property of PatientView, and no part may be reproduced without permission, or passed on to any third party without the permission of PatientView.